Concord Drugs Limited announced its audited standalone and consolidated financial results for the year ended March 31, 2026. The company reported a standalone total revenue of 78.77 Cr and a net profit of 1.05 Cr.

On a consolidated basis, total revenue was 75.88 Cr, with a net profit of 1.04 Cr.

These key financial updates were reviewed by the Audit Committee and approved by the Board, offering stakeholders a clear view of its annual performance.